Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A0SI
|
|||
| Former ID |
DNCL003393
|
|||
| Drug Name |
BAY 85-8501
|
|||
| Indication | Bronchiectasis [ICD-11: CA24; ICD-10: J47] | Phase 2 | [1] | |
| Company |
Bayer HealthCare Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H17F3N4O3S
|
|||
| Canonical SMILES |
CC1=C(C(N(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C)C3=C(C=C(C=C3)C#N)S(=O)(=O)C)C#N
|
|||
| InChI |
1S/C22H17F3N4O3S/c1-13-18(12-27)20(17-8-7-14(11-26)9-19(17)33(3,31)32)28(2)21(30)29(13)16-6-4-5-15(10-16)22(23,24)25/h4-10,20H,1-3H3/t20-/m1/s1
|
|||
| InChIKey |
YAJWYFPMASPAMM-HXUWFJFHSA-N
|
|||
| CAS Number |
CAS 1161921-82-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutrophil elastase (NE) | Target Info | Modulator | [2] |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037600) | |||
| REF 2 | Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.